JPMorgan Chase & Co. Has Lowered Expectations for Medtronic (NYSE:MDT) Stock Price

Medtronic (NYSE:MDT) had its price target decreased by analysts at JPMorgan Chase & Co. from $105.00 to $100.00 in a report issued on Wednesday, Marketbeat.com reports. The brokerage currently has a “neutral” rating on the medical technology company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 2.47% from the company’s current price.

Other equities analysts have also issued research reports about the stock. Leerink Partners lowered their price objective on shares of Medtronic from $120.00 to $119.00 and set an “outperform” rating for the company in a research report on Wednesday. William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Daiwa Securities Group upped their price objective on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Finally, Morgan Stanley lifted their target price on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. Sixteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $111.05.

Medtronic Stock Performance

NYSE MDT opened at $97.59 on Wednesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. Medtronic has a 1-year low of $79.55 and a 1-year high of $106.33. The business has a 50 day simple moving average of $99.10 and a two-hundred day simple moving average of $96.60. The stock has a market capitalization of $125.10 billion, a PE ratio of 27.18, a P/E/G ratio of 2.60 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same period in the prior year, the company earned $1.38 EPS. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts predict that Medtronic will post 5.46 EPS for the current fiscal year.

Institutional Trading of Medtronic

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. boosted its stake in shares of Medtronic by 38.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 39,635 shares of the medical technology company’s stock valued at $3,808,000 after purchasing an additional 11,060 shares during the period. Van Diest Capital LLC bought a new stake in Medtronic during the 4th quarter valued at about $370,000. Compound Planning Inc. boosted its position in Medtronic by 11.5% in the 4th quarter. Compound Planning Inc. now owns 16,396 shares of the medical technology company’s stock valued at $1,575,000 after buying an additional 1,694 shares during the period. TMB Capital Partners LLC purchased a new stake in Medtronic in the 4th quarter valued at about $1,690,000. Finally, Michels Family Financial LLC grew its stake in Medtronic by 3.1% in the 4th quarter. Michels Family Financial LLC now owns 7,339 shares of the medical technology company’s stock worth $705,000 after acquiring an additional 222 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat — Medtronic reported $1.36 EPS vs. $1.34 consensus and $9.02B revenue vs. $8.89B expected; company cited robust demand for heart devices, which supports near-term earnings and the company’s FY26 guidance. Medtronic beats quarterly profit estimates on robust demand for heart devices
• Positive Sentiment: Robotics and cardiovascular growth runway — analysts (e.g., TD Cowen) continue to highlight multi‑year growth potential from cardiovascular and robotics pipelines and have reiterated buy/outperform views, supporting upside vs. peers. Medtronic: Sustained Outperformance and Multi‑Year Growth Runway
• Neutral Sentiment: Earnings call / transcript available — investors can review management’s commentary on guidance, margin outlook and device demand to assess sustainability of the beat. Medtronic (MDT) Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst commentary is mixed — media coverage highlights divergent analyst views on Medtronic vs. peers (e.g., Globe and Mail pieces), reflecting differing weight on growth vs. risk. Analysts Conflicted on These Healthcare Names: Masimo (MASI) and Medtronic (MDT)
• Negative Sentiment: Analysts trimmed targets and forecasts after Q3 — several firms cut price targets (JPMorgan and Baird to ~$100; Leerink and others trimmed slightly) and lowered near‑term forecasts, which reduces sell‑side upside and can pressure the stock. Medtronic Analysts Cut Their Forecasts After Q3 Earnings JPMorgan adjusts price target on Medtronic
• Negative Sentiment: Legal/competitive overhang noted — coverage of Q3 calls out a “legal hit” and competitive pressure in certain device areas; these risks can weigh on multiples until resolved. Is Mixed Q3 Results, Robotics Win and Legal Hit Altering The Investment Case For Medtronic (MDT)?

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).